Trump’s Nuclear Revival Plan Boosts Uranium Prices, Sends US Miners Soaring
23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. The move comes after Regeneron Pharmaceuticals said earlier this month that it will acquire “substantially all” of 23andMe’s assets for $256 million. The drugmaker came out on top following a bankruptcy […]Read More